Gene Therapy for Noninfectious Uveitis
| Autor: | Robin R. Ali, Colin J Chu, S E Barker, Andrew D. Dick |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
biology
business.industry medicine.drug_class Genetic enhancement Genetic Therapy Disease medicine.disease_cause Receptor antagonist biology.organism_classification medicine.disease Uveitis Clinical trial Ophthalmology Treatment Outcome Immunology Lentivirus medicine Animals Humans Immunology and Allergy business Receptor Adeno-associated virus |
| Zdroj: | Ocular Immunology and Inflammation. 20:394-405 |
| ISSN: | 1744-5078 0927-3948 |
| DOI: | 10.3109/09273948.2012.726392 |
| Popis: | Noninfectious intraocular inflammatory disease remains a significant cause of visual loss, even with current systemic immunosuppression. Alternative novel treatments are thus required, particularly for severe forms of posterior uveitis. Encouraging results from several phase I/II clinical trials of gene therapy for monogenic retinal disorders have paved the way for the development of this approach for other ocular conditions. Gene therapy for uveitis offers the possibility of potent, self-regulating, long-term disease control following a single treatment and without systemic side effects. To date, gene therapy approaches using interleukin-10, interleukin-1 receptor antagonist, interferon-alpha, soluble TNF-alpha receptors, and alpha-MSH gene transfer have been used successfully to attenuate experimental animal models of uveitis. This review evaluates these preclinical studies, considers the route to clinical application, and explores future targets and approaches. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |